Avacta Group PLC has announced it will present new preclinical and translational data for its pre|CISION® platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting, which will take place from April 17 to April 22, 2026.
Two presentations will focus on AVA6103, a FAP-enabled peptide-drug conjugate designed to deliver the chemotherapy agent exatecan with a sustained-release mechanism. The compound has shown potent antitumour activity in preclinical studies.
Avacta will also showcase novel pre|CISION® candidates engineered to deliver dual therapeutic payloads to the tumour microenvironment following FAP-mediated cleavage, a strategy aimed at enhancing treatment effectiveness while limiting systemic toxicity.
The presentations underline Avacta’s continued progress in advancing its tumour-activated oncology drug delivery platform.
Details of the two presentations:
Title: AVA6103 is a FAP-enabled pre|CISION® peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity
Authors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Michelle Morrow, Francis Wilson
Poster number and Location: 5846, Section 17, Board 15
Session: Tumor Microenvironment, Multi-specifics, and Immunomodulation
Section: Experimental and Molecular Therapeutics
Timing: Tuesday, 21 April 2026, 2:00-5:00pm PDT
———————————————-
Title: Characterization and translational development of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage
Authors: Victoria Juskaite, Tom Clough, Ellen Watts , Alexa Kennedy, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Greg Billenness, Douglas Sammon, Sophie Brown, Curtis Rink , Ruairidh Edwards, Vidicha Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David Jones
Poster number and Location: 5656, Section 10, Board 26
Session: Antibody-Drug Conjugates and Linker Engineering 4
Section: Experimental and Molecular Therapeutics
Timing: Tuesday 21 April 2026, 2:00-5:00pm PDT
-Ends-
For further information from Avacta, please contact:
|
Avacta Group plc Christina Coughlin, Chief Executive Officer |
via Cohesion Bureau |
